Effect of chemical structure on properties of polyurethanes: Temperature responsiveness and biocompatibility

2018 ◽  
Vol 33 (5) ◽  
pp. 479-497 ◽  
Author(s):  
Aylin Komez ◽  
Senem Buyuksungur ◽  
Vasif Hasirci ◽  
Nesrin Hasirci

Polyurethanes are known as one of the most biocompatible and inherently blood-compatible materials and have a wide range of applications in the medical field due to their controllable structure and properties. Durability, elasticity, elastomeric structure, fatigue resistance, versatility, and easy acceptance by the biological media after the application makes these polymers preferable in medical area. In this study, polyurethane films were prepared using poly(propylene-ethylene glycol) and either toluene-2,4-diisocyanate or 4,4′-methylenediphenyl diisocyanate without adding any other ingredients such as solvent, catalyst, or chain extender to prevent negative effects of leachable molecules. Mechanical tests were performed at room temperature while swelling tests were conducted in water and phosphate-buffered saline at 4°C, 25°C, and 37°C. Temperature responsiveness was observed for the samples synthesized using toluene-2,4-diisocyanate and poly(propylene-ethylene glycol). These samples had more than 100% swelling at 4°C and about 4% swelling at 25°C and 37°C. Cytocompatibility tests were performed by culturing the samples and their extracts with mouse fibroblast cells (L929). Viability of human umbilical vein endothelial cells was studied to examine the compatibility of the films for blood contacting devices. Both toluene-2,4-diisocyanate and 4,4-methylenediphenyl diisocyanate–based polyurethane films showed no cytotoxic effect and good biocompatibility. Oxygen plasma treatment enhanced hydrophilicity of the films. After plasma treatment, human umbilical vein endothelial cell attachment on toluene-2,4-diisocyanate–based polyurethane films improved and 4,4-methylenediphenyl diisocyanate–based polyurethane films maintained their high cell affinity. Polyurethanes presenting temperature responsiveness, high biocompatibility, and high affinity for human umbilical vein endothelial cells were synthesized in medical purity and in a reaction media involving only diisocyanate and diol components without addition of any solvent, chain extender, or catalyst. Polyurethanes with these properties and as produced in this study are reported for the first time in the literature.

2016 ◽  
Vol 7 ◽  
pp. JCM.S39317 ◽  
Author(s):  
Yuya Nakamura ◽  
Masahiro Inagaki ◽  
Mayumi Tsuji ◽  
Toshihiko Gocho ◽  
Kazuaki Handa ◽  
...  

Background Because of the potential anti-inflammatory effects, linagliptin, a therapeutic dipeptidyl peptidase-4 inhibitor, is used as an effective drug for diabetic patients for whom inflammation is a prognosis-related factor. We investigated the anti-inflammatory mechanism of linagliptin using seven markers. Methods We pretreated human umbilical vein endothelial cells (HUVECs), with linagliptin and lipopolysaccharide (LPS). The cytosolic fractions were evaluated for protein kinase A (PKA), protein kinase B (PKB), protein kinase C (PKC), ratio of reactive oxygen species (ROS) and Cu/Zn superoxide dismutase (SOD), activator protein 1 (AP-1), and adenosine 3′,5′-cyclic monophosphate (cAMP). Results Linagliptin increased the PKA and PKC activities and the cAMP levels in LPS-treated cells. However, it inhibited LPS-induced PKB phosphorylation, ratio of ROS and Cu/Zn SOD, and LPS-stimulated AP-1 nuclear translocation. Conclusion We reaffirmed the anti-inflammatory and antioxidant effects of linagliptin. These effects might be related to the three protein kinases. Our findings suggest that linagliptin has a wide range of anti-inflammatory effects.


1989 ◽  
Vol 61 (01) ◽  
pp. 101-105 ◽  
Author(s):  
Bonnie J Warn-Cramer ◽  
Fanny E Almus ◽  
Samuel I Rapaport

SummaryCultured human umbilical vein endothelial cells (HUVEC) have been reported to produce extrinsic pathway inhibitor (EPI), the factor Xa-dependent inhibitor of factor VHa/tissue factor (TF). We examined the release of this inhibitor from HUVEC as a function of their growth state and in response to the induction of endothelial cell TF activity. HUVEC constitutively produced significant amounts of EPI at all stages of their growth in culture including the post-confluent state. Rate of release varied over a 3-fold range for primary cultures from 12 different batches of pooled umbilical cord cells. Constitutive EPI release was unaltered during a 6 hour period of induction of TF activity with thrombin or phorbol ester but slowed during longer incubation of the cells with phorbol ester. Whereas plasma contains two molecular weight forms of EPI, only the higher of these two molecular weight forms was demonstrable by Western analysis of HUVEC supernatants with 125I-factor Xa as the ligand.


1982 ◽  
Vol 47 (02) ◽  
pp. 128-131 ◽  
Author(s):  
F Esnard ◽  
E Dupuy ◽  
A M Dosne ◽  
E Bodevin

SummaryA preliminary characterization of a fibrinolytic inhibitor released by human umbilical vein endothelial cells in primary culture is reported. This molecule of Mr comprised between 2 × 105 and 106 and of μ2 mobility precipitates at 43% ammonium sulphate saturation and is totally adsorbed on Concanavalin A Sepharose 4 B. A possible relationship with a macroglobulins is discussed.


Sign in / Sign up

Export Citation Format

Share Document